エマウスライフサイエンス社、Generex Biotechnology Corporationと業務提携契約の締結へ


2017/1/27 09:50

AsiaNet 67237

エマウスライフサイエンス社、Generex Biotechnology Corporationと


カリフォルニア州トーランス市 -2017年1月27日-エマウスライフサイエンス社は本日、Generex Biotechnology Corporation(以下「Generex社」、OTCPink:GNBT)と業務提携契約を締結するための基本合意書(以下「合意書」)に署名したことを発表しました。エマウスライフサイエンス社はまず同社の発行済社外株式の51%に相当する持分を売却し、その後所定のマイルストーンが達成された場合には、Generex社に売却した51%の持分の内36%を回収する機会を有します。エマウスライフサイエンス社は2017年1月20日(金)に米国証券取引委員会(SEC)(www.sec.gov)に本合意書に関する臨時報告書(Form 8-K)を提出しました。この8-Kには取引条件の広範かつ詳細な説明が記載されています。


Generex社の社長兼最高経営責任者(CEO)であるJoseph Moscato氏は以下のように述べています。「私たちはエマウスライフサイエンス社との提携を歓迎しており、Generex社とエマウスライフサイエンス社、そして両社の株主が目指す目標を共に達成するために全力で協力していく所存です。」





本プレスリリースの医薬品の研究、開発、潜在的商業化に関する記述部分については、1995年米国民事証券訴訟改革法に規定の「将来の見通しに関する記述」に該当する記述が含まれています。これらの記述はあくまで現時点での予想によるものであり、物事を遅らせたり、転換したり、変更したりすることによって実際の結果が著しく異なってしまう要因となる不確定要素や固有のリスクを含んでいます。その他のリスクや不確定要素については、エマウスライフサイエンス社が米国証券取引委員会に提出した報告書に記載されており、同報告書には年次報告書(Form 10-K)および四半期決算書(Form 10-Q)が含まれています。エマウス社が今回提供している情報は、プレスリリース発表時点での情報であり、エマウス社は新たな情報、将来の事象、またその他の結果として、「将来の見通しに関する記述」を更新する義務を負いません。



Jim Heins

Senior Vice President

ICR Healthcare




Charles Butler

Senior Vice President

ICR Healthcare




Emmaus Life Sciences, Inc. Enters into Collaborative Agreement with Generex Biotechnology Corporation


TORRANCE, Calif., Jan. 27, 2017 /PRNewswire=KYODO JBN/ --

Emmaus announced today that it has entered into a letter of intent (the "LOI")

to establish a collaborative agreement with Generex Biotechnology Corporation

("Generex", OTCPink: GNBT).  Emmaus will sell an equity interest initially

worth 51% of Emmaus' issued and outstanding shares and Emmaus will have the

opportunity to earn back 36% of its capital stock out of the 51% interest sold

to Generex upon achieving certain milestones. The Company filed a Form 8-K

Current Report in respect of the LOI with the U.S. Securities and Exchange

Commission (SEC) (www.sec.gov) on Friday, January 20, 2017.  That 8-K provides

comprehensive and detailed descriptions of the transaction terms.

Generex is working toward rebuilding its company with a plan toward up-listing

to a major stock exchange. Emmaus is working toward achieving approval and

commercialization of its treatment for sickle cell disease.

Joseph Moscato, Generex President & Chief Executive Officer, stated: "We

welcome the association with Emmaus and are fully supportive of collectively

achieving the goals of Generex and Emmaus and their shareholders."

"Emmaus and Generex will collaborate to rebuild Generex as well as to grow

Emmaus in a synergistic fashion," commented Dr. Yutaka Niihara, MD, MPH,

Emmaus' Chief Executive Officer. "We at Emmaus look forward to working with the

team at Generex."

About Emmaus Life Sciences

Emmaus Life Sciences is engaged in the discovery, development and

commercialization of innovative treatments and therapies for rare diseases. The

company's research on sickle cell disease was initiated by Yutaka Niihara, MD,

MPH, Chairman and CEO of Emmaus, at the Los Angeles Biomedical Research

Institute at Harbor-UCLA Medical Center. For more information, please visit


Forward-Looking Statements

This press release contains forward-looking statements as that term is defined

in the Private Securities Litigation Reform Act of 1995, regarding the

research, development and potential commercialization of pharmaceutical

products. Such forward-looking statements are based on current expectations and

involve inherent risks and uncertainties, including factors that could delay,

divert or change any of them, and could cause actual outcomes and results to

differ materially from current expectations. Additional risks and uncertainties

are described in reports filed by Emmaus Life Sciences, Inc. with the U.S.

Securities and Exchange Commission, including its Annual Report on Form 10-K

and Quarterly Reports on Form 10-Q. Emmaus is providing this information as of

the date of this press release and does not undertake any obligation to update

any forward-looking statements as a result of new information, future events or


For more information, contact:

Media:                            Investors:

Jim Heins                         Charles Butler

Senior Vice President             Senior Vice President

ICR Healthcare                    ICR Healthcare

+1-203-682-8251                   +1-415-430-2079

james.heins@icrinc.com            charles.butler@icrinc.com  

SOURCE:  Emmaus Life Sciences